# GABA Pathways in Autism Spectrum Disorder (ASD)

> **NCT03678129** · NA · COMPLETED · sponsor: **King's College London** · enrollment: 109 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** AZD7325_10
- **DRUG:** AZD7325_20
- **DRUG:** Placebo
- **DRUG:** Clobazam

## Key facts

- **NCT ID:** NCT03678129
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-07
- **Primary completion:** 2025-06-27
- **Final completion:** 2025-06-27
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678129, "GABA Pathways in Autism Spectrum Disorder (ASD)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03678129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*